IAMA 004
Alternative Names: Her2-CD47-CD16 tri-specific antibody; IAMA-004; ISE-Tri-AbLatest Information Update: 08 Jul 2024
At a glance
- Originator Nanjing JSIAMA Biopharmaceuticals
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer